Differential fibrotic phenotypes of hepatic stellate cells within 3D liver organoids.


Journal

Biotechnology and bioengineering
ISSN: 1097-0290
Titre abrégé: Biotechnol Bioeng
Pays: United States
ID NLM: 7502021

Informations de publication

Date de publication:
08 2020
Historique:
received: 09 01 2020
revised: 16 04 2020
accepted: 07 05 2020
pubmed: 12 5 2020
medline: 11 8 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

Liver fibrosis occurs in most cases of chronic liver disease, which are somewhat common, but also a potentially deadly group of diseases. In vitro modeling of liver fibrosis relies primarily on the isolation of in vivo activated hepatic stellate cells (aHSCs) and studying them in standard tissue culture dishes (two-dimensional [2D]). In contrast, modeling of fibrosis in a biofabricated three-dimensional (3D) construct allows us to study changes to the environment, such as extracellular matrix (ECM) composition and structure, and tissue rigidity. In the current study, we used aHSCs produced through subcultures in 2D and encapsulated them in a 3D collagen gel to form spherical constructs. In parallel, and as a comparison, we used an established HSC line, LX-2, representing early and less severe fibrosis. Compared with LX-2 cells, the aHSCs created a stiffer environment and expressed higher levels of TIMP1 and LOXL2, all of which are indicative of advanced liver fibrosis. Collectively, this study presents a fibrosis model that could be incorporated with multi-cellular models to more accurately reflect the effects of a severe fibrotic environment on liver function.

Identifiants

pubmed: 32391915
doi: 10.1002/bit.27379
pmc: PMC7370813
mid: NIHMS1603516
doi:

Substances chimiques

Collagen 9007-34-5

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2516-2526

Subventions

Organisme : NIBIB NIH HHS
ID : T32 EB014836
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA202822
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA180149
Pays : United States

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Biophys J. 2014 Oct 21;107(8):1829-1840
pubmed: 25418164
World J Gastroenterol. 2016 Dec 28;22(48):10512-10522
pubmed: 28082803
Adv Drug Deliv Rev. 2017 Nov 1;121:27-42
pubmed: 28506744
Biochim Biophys Acta. 2013 Jul;1832(7):884-90
pubmed: 23434892
Dtsch Arztebl Int. 2013 Feb;110(6):85-91
pubmed: 23451000
J Cell Mol Med. 2007 Jul-Aug;11(4):704-22
pubmed: 17760834
PLoS One. 2016 Mar 21;11(3):e0151736
pubmed: 26998606
J Hepatol. 2007 May;46(5):955-75
pubmed: 17383048
Hepatology. 2008 Apr;47(4):1394-400
pubmed: 18307210
Cell. 2009 Nov 25;139(5):891-906
pubmed: 19931152
Methods Mol Biol. 2011;695:1-15
pubmed: 21042962
Gut. 2005 Jan;54(1):142-51
pubmed: 15591520
J Am Soc Nephrol. 2005 Nov;16(11):3211-21
pubmed: 16207831
Front Pharmacol. 2018 Jan 23;9:6
pubmed: 29410625
Int J Hepatol. 2012;2012:231210
pubmed: 22530132
Oncotarget. 2015 Sep 29;6(29):26729-45
pubmed: 26353929
Hepatology. 2001 May;33(5):1130-40
pubmed: 11343241
J Biol Chem. 2000 Jun 30;275(26):20136-45
pubmed: 10770928
Nat Rev Nephrol. 2016 Jun;12(6):325-38
pubmed: 27108839
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
Gut. 2006 Mar;55(3):403-8
pubmed: 16020491
World J Gastroenterol. 2018 Dec 7;24(45):5063-5075
pubmed: 30568384
Adv Drug Deliv Rev. 2017 Nov 1;121:3-8
pubmed: 28600202
Adv Drug Deliv Rev. 2017 Nov 1;121:133-146
pubmed: 28697953
Biomed Res Int. 2016;2016:2646212
pubmed: 27800489
PLoS One. 2013 Oct 08;8(10):e75692
pubmed: 24116068
J Transl Med. 2016 Sep 29;14(1):281
pubmed: 27681697
World J Gastroenterol. 2014 Dec 21;20(47):17756-72
pubmed: 25548474
Matrix Biol. 2005 Oct;24(7):451-8
pubmed: 16095890
World J Hepatol. 2017 Sep 18;9(26):1092-1100
pubmed: 28989565
PLoS One. 2019 May 15;14(5):e0216537
pubmed: 31091287
J Clin Invest. 2013 May;123(5):1902-10
pubmed: 23635788
Scand J Gastroenterol. 2014 Sep;49(9):1103-10
pubmed: 25048331
Proc Natl Acad Sci U S A. 2017 May 2;114(18):4679-4684
pubmed: 28416697
World J Gastroenterol. 2018 Oct 21;24(39):4436-4447
pubmed: 30357021
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Protoc. 2015 Feb;10(2):305-15
pubmed: 25612230
Drugs. 2019 Jun;79(9):903-927
pubmed: 31119644
J Immunol. 2001 Dec 15;167(12):7017-26
pubmed: 11739522

Auteurs

Matthew Brovold (M)

Wake Forest School of Medicine, Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.

Dale Keller (D)

Wake Forest School of Medicine, Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.
School of Medicine, Meharry Medical College, Nashville, Tennessee.

Shay Soker (S)

Wake Forest School of Medicine, Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH